Business Wire

Cubans Protest EU Financing of Havana Regime Amid Rising Tensions

24.2.2026 08:05:00 CET | Business Wire | Press Release

Share

Cubans from across the United States gathered today in Washington, D.C., outside the Delegation of the European Union, to denounce the EU’s complicity in financing Cuba’s communist state. Protesters held signs reading, “EU, don’t fund the dictatorship,” “Democracies should not fund dictatorships,” and “This march would get me killed in Cuba.”

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260223106922/en/

Cubans from across the United States gathered yesterday in Washington, D.C., outside the Delegation of the European Union, to denounce the EU’s role in financing Cuba’s communist state. The demonstration featured leading Cuban opposition groups including the Assembly of the Cuban Resistance and Cuban Freedom March along with former Cuban political prisoners, Veterans of the Bay of Pigs, Florida State Senator Alexis Calatayud, Miss Universe Cuba 2025 Lina Luaces, and television personality Lili Estefan. Photo: Assembly of the Cuban Resistance.

The demonstration featured leading Cuban opposition groups including the Assembly of the Cuban Resistance and Cuban Freedom March along with former Cuban political prisoners, Veterans of the Bay of Pigs, Florida State Senator Alexis Calatayud, Miss Universe Cuba 2025 Lina Luaces, and television personality Lili Estefan.

Speakers at the rally criticized the Castro regime’s human rights record, highlighting the Cuban state’s sending of mercenaries to support Russia’s war effort in Ukraine. This follows an unprecedented move in late January by the European Parliament to approve an amendment calling for the revision and suspension of the Political Dialogue and Cooperation Agreement (PDCA) that since 2017 governs the relationship between the European Union (EU) and the Cuban regime. The approved amendment calls on the European Commission to ‘use all available instruments, without excluding any’, to ensure compliance with democratic and human rights standards on the island.

“The reality is that millions of euros supposedly going to ‘sustainability programs’ actually go into the hands of those closest to the regime who use it for further repression and their own projects and benefit,” said Orlando Gutierrez-Boronat, spokesperson for the Cuban Democratic Directorate and a member of the Assembly of the Cuban Resistance.

The demonstration comes amid escalating tensions on the island. Reports this week alleged that approximately 10 political prisoners died in custody after protesting the death of a 19-year-old inmate who was found hanging in his cell following weeks of complaints about food shortages and lack of medical care. These claims have intensified criticism of the Cuban state’s repressive apparatus, prison conditions and treatment of dissidents.

In Washington, the administration of Donald Trump has maintained pressure on Havana through strengthened sanctions and restrictions on oil shipments to the island. Protest organizers contrasted that approach with policies in parts of Europe, particularly Spain.

In July 2025, Spain approved a debt restructuring mechanism aimed at forgiving part of Cuba’s debt in order to reinvest in electricity infrastructure and food security projects. The initiative forms part of a broader agreement linked to negotiations with the Paris Club.

Under the so-called “Debt Conversion Program,” Spain planned to forgive and redirect approximately €375 million toward sustainable development projects. However, new developments have complicated the picture. On February 21, 2026, Spanish-language media outlet Infobae revealed that more than 150 Spanish companies, most of them small and medium-sized enterprises, formally requested extraordinary financial support from the Spanish government for roughly €255 million in unpaid debts owed by the Cuban state. Several of these firms have reportedly entered bankruptcy proceedings due to prolonged non-payment.

The protest underscores the belief that the corruption and violent nature attributed to Cuba’s communist government make it a highly volatile and risky partner for the European Union.

“Continued financial engagement and debt-relief directed toward the regime ultimately strengthen state institutions accused of repression, rather than benefiting the Cuban people,” continued Gutierrez-Boronat. “The message of protestors was clear – financing initiatives directed through the current system risks perpetuating political repression and deepening the suffering of ordinary citizens.”

About the Assembly of the Cuban Resistance

The Assembly of the Cuban Resistance is a parliament in exile, comprised of a host of non-governmental organizations working together to bring freedom to the oppressed people of Cuba.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260223106922/en/

Contacts

For more information:
Silvia Gutiérrez-Boronat
Directorio Democratico
silvia@directorio.org
786-287-0775

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye